PROPHYLACTIC ADMINISTRATION OF 17 ALPHA-HYDROXYPROGESTERONE CAPROATE (17P) IN CLINICAL PRACTICE: THE IMPACT ON RATES OF PRETERM BIRTH

被引：0
|
作者：
Rebarber, Andrei [1 ]
Fox, Nathan S. [1 ]
Klauser, Chad K. [1 ]
Gandhi, Manisha [2 ]
Rhea, Debbie [3 ]
Istwan, Niki [3 ]
Stanziano, Gary [3 ]
Saltzman, Daniel [1 ]
机构：
[1] Maternal Fetal Med Associates, New York, NY USA
[2] Mt Sinai Med Ctr, New York, NY 10029 USA
[3] Matria Healthcare, Clin Res, Marietta, GA USA
来源：
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2008年 / 199卷 / 06期
关键词：
D O I：
10.1016/j.ajog.2008.09.334
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：S96 / S96
页数：1
相关论文
共 50 条
  • [1] 17 alpha-hydroxyprogesterone caproate, HIV, and preterm birth
    Ntozini, Robert
    Prendergast, Andrew J.
    LANCET HIV, 2021, 8 (10): : E600 - E601
  • [2] Smoking, 17 Alpha-Hydroxyprogesterone Caproate, and Preterm Birth
    Heyborne, Kent D.
    Allshouse, Amanda A.
    AMERICAN JOURNAL OF PERINATOLOGY, 2016, 33 (12) : 1191 - 1197
  • [3] The role of 17 alpha-hydroxyprogesterone caproate in the prevention of preterm birth
    Meis, Paul J.
    WOMENS HEALTH, 2006, 2 (06) : 819 - 824
  • [4] The use of 17 Alpha-Hydroxyprogesterone caproate (17P) in women with cervical cerclage
    Rebarber, Andrei
    Belogolovkin, Victoria
    Russo-Stieglitz, Karen
    Rhea, Debbie
    Stanziano, Gary
    Saltzman, Daniel
    OBSTETRICS AND GYNECOLOGY, 2007, 109 (04): : 40S - 40S
  • [5] The use of 17 alpha-hydroxyprogesterone caproate (17P) in women with cervical cerclage
    Rebarber, Andrei
    Cleary-Goldman, Jane
    Istwan, Niki B.
    Rhea, Debbie J.
    Desch, Cheryl
    Russo-Stieglitz, Karen
    Saltzman, Daniel H.
    AMERICAN JOURNAL OF PERINATOLOGY, 2008, 25 (05) : 271 - 275
  • [6] The influence of cervical length on the effectiveness of 17 alpha-hydroxyprogesterone caproate (17P) in the clinical setting
    Page, Dexter
    Istwan, Niki
    Rhea, Debbie
    Stanziano, Gary
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2009, 201 (06) : S60 - S60
  • [7] Conformity with treatment standards and pregnancy outcomes in patients receiving 17 alpha-hydroxyprogesterone caproate (17p) for preterm birth prophylaxis
    Istwan, Niki
    Rhea, Debbie
    Desch, Cheryl
    Stanziano, Gary
    Gonzalez-Quintero, Victor Hugo
    Tudela, Felipe Jose
    Romary, Leticia Maria
    Cordova, Yvette C.
    Achille, Fabienne
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2011, 204 : S81 - S81
  • [8] Estimated effect of 17 alpha-hydroxyprogesterone caproate on preterm birth in the United States
    Petrini, JR
    Callaghan, WM
    Klebanoff, M
    Green, NS
    Lackritz, EM
    Howse, JL
    Schwarz, RH
    Damus, K
    OBSTETRICS AND GYNECOLOGY, 2005, 105 (02): : 267 - 272
  • [9] Gestational age at initiation of 17 alpha-hydroxyprogesterone caproate (17P) and rate of preterm births in singleton gestations with a history of preterm delivery
    Gonzalez-Quintero, V
    Istwan, N
    Rhea, D
    Cotter, A
    Hoffman, MC
    Smarkusky, L
    Guell, G
    Stanziano, G
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (06) : S53 - S53
  • [10] Does administration of 17 alpha-hydroxyprogesterone caproate for preterm birth prevention alter the incidence of gestational diabetes?
    Rebarber, A
    Istwan, N
    Russo-Stieglitz, K
    Rand, L
    Rhea, D
    Stanziano, G
    Saltzman, D
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2005, 193 (06) : S182 - S182
12345